Albert Kim, MD, PhD

Advisor

Albert Kim, is an Advisor at Raven. Albert is currently the Chief Medical Officer of Imbria Pharmaceuticals, where he leads clinical development of cardiovascular therapies. A physician-scientist, he brings more than two decades of experience in cardiovascular medicine, translational science, and therapeutic development.

Before joining Imbria, Dr. Kim was a Venture Partner at Raven and Chief Medical Officer of the Raven Blackbird Development Team. He previously served as Chief Medical Officer of Cytel and held senior clinical development roles at Novartis and Pfizer. At Pfizer, he was Vice President and Clinical Research Head for the Internal Medicine Research Unit, overseeing programs in cardiometabolic disease and the legacy neuroscience portfolio. Earlier, he was a medical reviewer in the FDA’s Division of Cardiac Devices and practiced clinical medicine for 18 years.

Dr. Kim is a Fellow of the American College of Cardiology and the Heart Rhythm Society. He earned an undergraduate degree in biomedical engineering from Harvard and MD and PhD degrees from UCLA. He completed his internal medicine residency at Brigham and Women’s Hospital, cardiology fellowship at Massachusetts General Hospital, and clinical cardiac electrophysiology training at UCSF.